Antiarrhythmics Contraindicated in Structural Heart Disease
Class IC antiarrhythmic drugs (flecainide and propafenone) should not be used in patients with structural heart disease, including prior myocardial infarction, coronary artery disease, impaired left ventricular function, significant left ventricular hypertrophy, or moderate-to-severe valvular disease. 1
Primary Contraindications
Class IC Agents: Flecainide and Propafenone
- Absolutely contraindicated in patients with:
These restrictions stem from increased proarrhythmic risk and potential for ventricular tachyarrhythmias in structural heart disease 3, 4. The evidence is consistent across multiple guidelines that these agents are safe only in patients without structural heart disease 5, 6.
Dronedarone
- Contraindicated in:
The ANDROMEDA and PALLAS trials demonstrated harm with dronedarone in patients with moderate-to-severe heart failure 7.
Safe Alternatives in Structural Heart Disease
When antiarrhythmic therapy is needed in patients with structural heart disease, the following agents are appropriate:
First-Line Options:
- Amiodarone: The most broadly safe option across all forms of structural heart disease, including HFrEF, coronary disease, and significant LVH 1, 8, 6, 9
- Beta-blockers: Reduce mortality in heart failure and post-MI patients 4, 10
Alternative Class III Agents:
- Sotalol: Can be used in structural heart disease but requires monitoring for QT prolongation and torsades de pointes 5
- Dofetilide: Acceptable in structural heart disease and coronary disease, but requires inpatient initiation with QT monitoring 5, 6
For Acute Management:
- Ibutilide or procainamide (IV): May be considered for cardioversion in structural heart disease patients without hypotension or heart failure manifestations, with close monitoring for at least 6 hours 1
Clinical Algorithm for Drug Selection
Step 1: Assess for structural heart disease
- Prior MI, CAD, LV dysfunction (any degree), significant LVH, or moderate+ valvular disease
Step 2: If structural heart disease is ABSENT:
Step 3: If structural heart disease is PRESENT:
- Avoid flecainide and propafenone entirely
- Use amiodarone as primary option 1, 8, 9
- Consider sotalol or dofetilide as alternatives (with appropriate monitoring) 5
Step 4: If NYHA Class III-IV heart failure:
Critical Pitfalls to Avoid
Do not extrapolate "stable CAD" as safe for Class IC agents: Even stable coronary disease without recent MI remains a contraindication per current guidelines 1, 2, though emerging research suggests this may warrant reconsideration in highly selected cases 11, 12
Do not use dronedarone in permanent AF: This is explicitly contraindicated regardless of other factors 7
Do not combine dronedarone with digoxin: Increased sudden mortality signal in PALLAS trial 7
Do not use Class IC agents with AV nodal blockers initially: Risk of 1:1 atrial flutter conduction; combine with beta-blockers or calcium channel blockers 1
The evidence base strongly supports these restrictions, with Class IC contraindications rooted in increased mortality demonstrated in the CAST trial and consistently reinforced across contemporary guidelines 3, 4, 10, 13.